Get started

NRBO

NRBO | Huge Gains Incoming | OversoldNeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
NASDAQ:NRBOLong
by DivergenceSeeker
12
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday? Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001, a proprietary oral niclosamide formulation, as a treatment for moderate to severe COVID-19." "we expect to report preclinical in vitro data demonstrating Gemcabene's ability to treat COVID-19 variants alone and in combination with ANA001." "NeuroBo has the financial foundation to fund operations at the current level into the fourth quarter of 2021 and we expect to achieve a number of value-creating milestones with our COVID-19 programs in the coming months." Besides the Covid-19 treatment, NeuroBo Pharmaceuticals has a current portfolio of four drug candidates focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. The Market Cap if only 88.473Mil at the time or writing!
NASDAQ:NRBOLong
by TopgOptions
4
NRBO Technical Analysis 🧙NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing therapies for patients with diabetic neuropathy and Alzheimer's disease. Its product candidate comprises NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy; NB-02, which treat the symptoms of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid-beta plaque deposition; Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:NRBOLong
by unfair_advantage